Estrella Immunopharma, Inc. (NASDAQ:ESLA) has announced a major milestone in its STARLIGHT-1 Phase I/II clinical trial, dosing the first patient in the second cohort of its dose escalation study ...

Tesla’s long-promised fleet of self-driving robotaxis is finally arriving — sort of. CEO Elon Musk says the company will ...

Elon Musk has long been an advocate for human travel to Mars and setting up bases on other planets, but has yet to put any ...

Fintel reports that on July 24, 2024, RBC Capital upgraded their outlook for Estée Lauder Companies (WBAG:ESLA) from Sector Perform to Outperform. There are 1,779 funds or institutions reporting ...

“The Ministry of Finance [also] reported to parliament that an amount of GH¢3,151.74million was realised in ESLA receipts for 2017. This position is irreconcilable with computed ESLA receipts ...

ESLA has announced that approximately 90% of non-sovereign bondholders have successfully tendered their bonds. This follows an announcement on September 16, 2024, to buy back all the outstanding ...

Fintel reports that on August 22, 2024, Piper Sandler upgraded their outlook for Estée Lauder Companies (WBAG:ESLA) from Neutral to Overweight. There are 1,728 funds or institutions reporting ...

EMERYVILLE, Calif., March 05, 2025--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical ...

President John Dramani Mahama has expressed concerns over the mismanagement of revenues generated from the Energy Sector Levy Act (ESLA). According to him, the funds were not utilised for their ...

The report further disclosed that actual lodgments into ESLA accounts lagged behind collections by GH¢ 600.78 million, representing a 7% shortfall of the GHS 8.67 billion target. Nonetheless the ...

The weekly rent for 9 Esla Drive, Roxburgh Park is $650 per week. When is 9 Esla Drive, Roxburgh Park available to rent? 9 Esla Drive, Roxburgh Park is available to rent now. How much is the ...

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company ...